US osteoporosis drugs market to cross $4 billion by 2021: Pharmaion Report
Increasing prevalence of osteoporosis and growing ageing population coupled with new product launches to drive US osteoporosis drugs market through 2021.
According to Pharmaion report, "United States Osteoporosis Drugs Market Opportunities, 2011–2021", the osteoporosis drugs market in the US is projected to cross US$4 billion by 2021. Growth in the market is anticipated on account of increasing prevalence of osteoporosis, rising ageing population and growing number of post-menopausal women. Moreover, increasing number of international players and growing awareness regarding osteoporotic care among consumers is projected to drive the osteoporosis drugs market in the US over the next 5 years.
In 2011, According to the National Osteoporosis Foundation, 10 million individuals aged 50 years or above (2 million men and 8 million women) in the US, were suffering from the disease. Additionally, almost 34 million individuals had low bone mass, which placed them at a high risk for developing osteoporosis. With growing ageing population, the number of people suffering from osteoporosis is anticipated to increase to 14 million individuals, and more than 47 million cases of low bone mass are expected to be reported by 2020.
Growing adoption of generic products, patent expiry and various side-effects related to osteoporosis drugs are some of the major factors restraining growth of osteoporosis drugs market in the country. On the basis of drug class, the market has been segmented into six categories, namely, Bisphosphonates, Calcitonins, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone (PTH), Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and others. Among these categories, Bisphosphonates dominated the US osteoporosis drugs market in 2015. However, owing to patent expiries and associated side-effects of Bisphosphonates, RANKL is anticipated to emerge as the largest drug category by end of 2021.
"With growing adoption of Cathepsin K Inhibitors, Wnt Signaling Antibodies and Osteoblastic Cell Therapy, US osteoporosis drugs market will continue to exhibit promising growth in the coming years. Moreover, various federal agencies in the US are working towards setting up public workshops to discuss challenges and solutions related to osteoporosis drug development. These workshops offer a unified platform to clinicians, researchers and scientists to share their inputs for better osteoporosis drug development. All these factor present a positive outlook for osteoporosis drugs market, especially in the US," said Mr Karan Chechi, Research Director with Pharmaion Consultants, a research based global management consulting firm focused on pharma and healthcare industry.
"United States Osteoporosis Drugs Market Opportunities, 2011–2021" has analysed the potential of osteoporosis drugs market in the US and provides statistics and information on market sizes, shares and trends. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with essential drivers and key challenges faced by the US osteoporosis drugs market.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance